Objective: to clarify the clinical and diagnostic features of arterial hypertension in patients with mild and moderate forms of COVID-19, taking into account the elapsed time. Material and methods. We examined 116 patients aged 44-60 years who were admitted to the hospital with uncontrolled stage 2 arterial hypertension, 96 of them had mild and moderate COVID-19. The patients were divided into two groups: the first group up to 12 weeks after suffering COVID-19 and the second group after 12 weeks. The examination included echocardiography and ambulatory blood pressure (BP) monitoring. Results. In post-COVID-19 patients, the ratio of daytime to nighttime systolic BP was statistically significantly lower than in disease-free patients (p <0,001, p1 =0,015). There was a decrease in the daily BP index in the group 1 and group 2 (11.6±0.8% and 12.2±1.2%, respectively, p=0,001). Among patients after COVID-19, non-dippers were detected, more often in group 1 (9 people (17.6%) versus 2 people (4.4%) (x2=4.18, p=0.042). Conclusion. Arterial hypertension in patients who underwent mild and moderate COVID-19 was characterized by an insufficient decrease in systolic blood pressure at night, the presence of non-dippers with positive dynamics after 12 weeks from the onset of the infectious process.
Aim. Аnalysis of the efficacy and safety of complex therapy including fixed-dose combinations of long-acting bronchodilators (FCLB) in comorbid patients with an exacerbation of chronic obstructive pulmonary disease (COPD) of the spirometry grades III – IV and hypertension.Methods. A total of 232 patients with an exacerbation of COPD of the spirometry grades III – IV were examined. 174 (75%) patients were diagnosed with the third grade (GOLD III), 58 (25%) – with the fourth spirometry grade (GOLD IV). In the GOLD III group, a moderate exacerbation was diagnosed in 22 (12.6%), severe — in 152 (87.4%). In the GOLD IV group, a moderate exacerbation was diagnosed in 5 (8.5%), severe — in 53 (91.5%), respectively. The patients were divided into 4 groups. Group 1 included 50 patients with an exacerbation of COPD of the spirometry grades III – IV without hypertension; Group 2 – 56 patients with an exacerbation of COPD and concomitant hypertension; Group 3 – 64 patients with an exacerbation of COPD without hypertension, who received FCLB in addition to standard therapy from the 3rd day of hospitalization; Group 4 – 62 patients with an exacerbation of COPD of the spirometry grades III – IV and concomitant hypertension who received FCLB in addition to standard therapy from the 3rd day of hospitalization. The examination included clinical and instrumental methods: the changes in the clinical signs and symptoms, the dyspnea index (according to the mМRS scale), the saturation of hemoglobin with oxygen (SaO2), spirometry, heart rate variability, the frequency and nature of arrhythmias, and systolic and diastolic blood pressure (BP).Results. A sympathicotonic disorder of the autonomic balance was revealed in patients with exacerbation of COPD of the spirometry grades III – IV. This tendency intensified in the patients with concomitant hypertension, which indicated an additional negative effect of comorbid hypertension on the studied parameters. Aggravation of sympathicotonia could be a trigger for an increase in ectopic rhythm disturbances, including high-grade ventricular extrasystoles. In the groups with concomitant hypertension, rhythm disturbances were more frequent (p < 0.05). The inclusion of FCLB in the complex therapy of exacerbation of COPD of the spirometry grades III – IV made it possible to improve the condition of patients significantly: to reduce the dyspnea index on the mМRS scale, increase SaО2 and FEV1 (p < 0.05), achieve clinical improvement in COPD faster and shorten the hospitalization period. As a result of the rapid and effective relief of exacerbation of COPD, the influence of pathogenic factors on the cardiovascular system in the examined patients decreased. The addition of FCLB to the treatment COPD with and without comorbid hypertension did not have a negative effect on heart rate variability, did not aggravate rhythm disturbances, and did not destabilize the BP.Conclusion. The positive clinical effects of the inclusion of FCLB in the complex therapy of exacerbation of COPD of the spirometry grades III – IV in patients with comorbid hypertension led to a decrease in shortness of breath, an improvement in respiratory functions, a decrease in tissue hypoxia and eliminated possible adverse events of this group of drugs.
The purpose of the review: to summarize the information available in the literature and to present to the practitioner information on the relationship of diseases of the gastrointestinal tract with cardiovascular pathology.Basic provisions. The comorbidity of diseases of the gastrointestinal tract and cardiovascular pathology (CVP) is due to similar risk factors and pathogenetic mechanisms. The results of scientifi c studies of patients with gastrointestinal tract pathology indicate higher cardiac risks and the incidence of CVP in comparison with the general population.Conclusion. Gastrointestinal disorders can act as risk factors, links in pathogenesis, elements of the clinical picture of CVP. A multidisciplinary approach is needed in the treatment of patients with chronic gastrointestinal pathology in order to best address the underlying problems and existing cardiovascular diseases in this category.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.